Skip to main content
An official website of the United States government
Email

Toward Translation of Nanotechnology Cancer Interventions (TTNCI)

The TTNCI program supports researchers in translating nanotechnology-based cancer interventions into clinical products. These interventions rely on nanoparticle formulations and nano-devices. The TTNCI program encourages applications focused on advanced preclinical research, aiming to advance both diagnostic and therapeutic technologies. TTNCI awards are designed to mature experimental and novel nanotechnology-based interventions with strong potential to improve their performance. Some may also address cancers which suffer from limited availability of therapeutic or diagnostic options. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions through the NCI Experimental Therapeutics (NExT) program or other NCI translational initiatives.

Currently active TTNCI projects are listed below:

  • Mekhail Anwar/Bruce Cohen – UNIVERSITY OF CALIFORNIA, SAN FRANCISCO – Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles
  • Venessa Bellat –WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY – Customized Nanofibers with Preferential Lung-targeting Properties for Treating Metastatic Pulmonary Tumors
  • Xiaohu Gao – UNIVERSITY OF WASHINGTON – Targeted RNA Delivery Using Ribonucleoprotein
  • Cesar Castro/Hakho Lee – MASSACHUSETTS GENERAL HOSPITAL – High Throughput Nanoplasmonic Exosome Testing (NEXT) of Immunotherapies in Bladder Cancer
  • Wen Jiang/Betty Kim – UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER –Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy
  • Alexander Kabanov – UNIVERSITY OF NORTH CAROLINA CHAPEL HILL – Toward Translation of Nanoformulated Paclitaxel-Platinum Combination
  • Raghuramann Kannan – UNIVERSITY OF MISSOURI-COLUMBIA – Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug Resistant NSCLC 
  • Glen Kwon – UNIVERSITY OF WISCONSIN-MADISON – Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
  • Chun Li – UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER –Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy
  • Alexander Ljubimov – CEDARS-SINAI MEDICAL CENTER – Targeting Tumor Microenvironment by Nanoimmunodrugs for Glioma Treatment
  • Julie Rhoades/Craig Duvall – VANDERBILT UNIVERSITY MEDICAL CENTER – Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors
  • Matthias Stephan – FRED HUTCHINSON CANCER RESEARCH CENTER – Developing Macrophage Reprogramming mRNA Nanocarriers for Initial Clinical Testing
  • Shan Wang – STANFORD UNIVERSITY – Rapid and Affordable Magneto-Nanosensors for ctDNA-Guided Lung Cancer Management
  • John Tanner Wilson – VANDERBILT UNIVERSITY – Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma 
  • Jin Xie/Zibo Li/William Kim – UNIVERSITY OF GEORGIA – Development of A Novel Biodegradable Inorganic Nanoparticle Therapeutic for Cancer
  • Hu Yan/Kristoffer Valerie – MISSOURI UNIVERSITY OF SCIENCE & TECHNOLOGY– PEAMOtecan, A Novel Chronotheranostic Polymeric Drug for Brain Cancer with Potential Multi-Prong Drug Delivery Capability
  • Yoon Yeo/Stephen Kron – PURDUE UNIVERSITY –Systemic Delivery of siRNA by Nanosac for Checkpoint Blockade Immunotherapy of Head and Neck Squamous Cell Cancer

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Toward Translation of Nanotechnology Cancer Interventions (TTNCI) was originally published by the National Cancer Institute.”

Email